SCHEMBL2741010

SCHEMBL2741010

COC(=O)c1ccccc1S(=O)(=O)Nc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.66
GAA P10253 1/20 0.66
KMT2A Q03164 2/20 0.65
MEN1 O00255 1/20 0.65
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
CA5A P35218 1/20 0.61
CA9 Q16790 1/20 0.61
MAPT P10636 2/20 0.58
PTPN2 P17706 1/20 0.57
PTPN1 P18031 1/20 0.57
PTPN5 P54829 1/20 0.57
SLC40A1 Q9NP59 1/20 0.55
MMP2 P08253 2/20 0.55
MMP13 P45452 2/20 0.55
BRD4 O60885 3/20 0.54
ALOX15 P16050 1/20 0.53
MMP1 P03956 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14150131 0.91 MEN1 (0.63) NPC1GAAKMT2AMEN1CA1
SCHEMBL96178 0.88 KMT2A (0.63) NPC1GAAKMT2AMEN1CA1
SCHEMBL12167785 0.88 MMP2 (0.67) NPC1GAAKMT2AMEN1CA1
SCHEMBL14106146 0.87 KMT2A (0.59) NPC1GAAKMT2AMEN1CA1
SCHEMBL1050952 0.84 MEN1 (0.66) NPC1GAAKMT2AMEN1MAPT
SCHEMBL15482267 0.84 MMP2 (0.60) NPC1GAAKMT2AMEN1CA1
SCHEMBL2905661 0.83 MMP2 (0.68) KMT2AMEN1CA1CA2CA9
SCHEMBL17078023 0.83 KMT2A (0.57) NPC1GAAKMT2AMEN1CA1
SCHEMBL10781994 0.82 CA1 (0.63) NPC1GAAKMT2AMEN1CA1
SCHEMBL21268180 0.81 CA1 (0.67) NPC1GAAKMT2AMEN1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 NPC1 2195/4885GAA 4586/4885KMT2A 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.